Duration of anti-resorptive effects of low dose zoledronate in osteopenic postmenopausal women: A randomized, placebo-controlled trial

Journal of Bone and Mineral Research, 06/13/2013

Annual intravenous administration of 5mg zoledronate decreases fracture risk, but the optimal dosing regimen for zoledronate has not been determined. The data demonstrate that single administrations of zoledronate 1mg or 2.5mg produce anti–resorptive effects that persist for at least 2y. Trials assessing the anti–fracture efficacy of intermittent low doses of zoledronate, in particular the 2.5mg dose, are justified.

Print Article Summary Cat 2 CME Report